DiaMedica Therapeutics Inc. (DMAC) 10-Year Financial Performance & Capital Metrics

DMAC • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Show more

Revenue $0
EBITDA -$27M -25.5%
Net Income -$24M -26.1%
EPS (Diluted) -0.60
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -53.27% -13.9%
ROIC -47.11% -10.0%
Debt/Equity 0.01 +6.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 90 (top 10%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 24.1% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-47.09%

EPS CAGR

10Y-

5Y-

3Y-

TTM-26.79%

ROCE

10Y Avg-233.03%

5Y Avg-51.89%

3Y Avg-48.46%

Latest-57.8%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	500K	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-1%	-	-	-	-	-
Cost of Goods Sold+	4.46K	2.21K	4K	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-4.46K	-2.21K	-4K	500K	0	0	0	0	0	0
Gross Margin %	-	-	-	1%	-	-	-	-	-	-
Gross Profit Growth %	-	0.5%	-0.81%	126%	-1%	-	-	-	-	-
Operating Expenses+	1.31M	2.48M	4.28M	6.05M	11.59M	12.7M	13.65M	14M	21.27M	26.68M
OpEx % of Revenue	-	-	-	12.09%	-	-	-	-	-	-
Selling, General & Admin	423.35K	718.04K	1.31M	2.74M	3.69M	4.49M	4.88M	6.16M	8.16M	7.62M
SG&A % of Revenue	-	-	-	5.48%	-	-	-	-	-	-
Research & Development	886.07K	1.76M	3.21M	4.52M	7.9M	8.21M	8.77M	7.84M	13.11M	19.06M
R&D % of Revenue	-	-	-	9.04%	-	-	-	-	-	-
Other Operating Expenses	3K	0	6K	-68K	0	0	0	0	0	0
Operating Income+	-1.31M	-2.48M	-4.52M	-6.76M	-11.59M	-12.7M	-13.65M	-14M	-21.27M	-26.68M
Operating Margin %	-	-	-	-13.52%	-	-	-	-	-	-
Operating Income Growth %	0.73%	-0.9%	-0.82%	-0.5%	-0.71%	-0.1%	-0.07%	-0.03%	-0.52%	-0.25%
EBITDA+	-1.31M	-2.48M	-4.51M	-6.75M	-11.57M	-12.68M	-13.62M	-13.98M	-21.24M	-26.64M
EBITDA Margin %	-	-	-	-13.49%	-	-	-	-	-	-
EBITDA Growth %	0.73%	-0.9%	-0.82%	-0.49%	-0.72%	-0.1%	-0.07%	-0.03%	-0.52%	-0.25%
D&A (Non-Cash Add-back)	4.11K	2.21K	4K	15K	21K	21K	24K	25K	30K	39K
EBIT	-1.5M	-2.15M	-4.26M	-5.55M	-11.59M	-12.7M	-13.65M	-14M	-21.27M	-26.68M
Net Interest Income+	-42.22K	-46.65K	0	0	0	0	0	0	0	2.3M
Interest Income	1.74K	1.73K	0	0	0	0	0	0	0	2.3M
Interest Expense	43.95K	48.38K	0	0	0	0	0	0	0	0
Other Income/Expense	-104.38K	280.63K	259K	747K	975K	434K	82K	353K	1.93M	2.27M
Pretax Income+	-1.43M	-2.2M	-4.26M	-5.65M	-10.62M	-12.27M	-13.56M	-13.65M	-19.34M	-24.41M
Pretax Margin %	-	-	-	-11.31%	-	-	-	-	-	-
Income Tax+	12.45K	22.31K	-9K	80K	31K	27K	28K	28K	43K	30K
Effective Tax Rate %	1.01%	1.01%	1%	1.01%	1%	1%	1%	1%	1%	1%
Net Income+	-1.44M	-2.22M	-4.26M	-5.73M	-10.65M	-12.29M	-13.59M	-13.68M	-19.38M	-24.44M
Net Margin %	-	-	-	-11.47%	-	-	-	-	-	-
Net Income Growth %	0.7%	-0.54%	-0.92%	-0.35%	-0.86%	-0.15%	-0.11%	-0.01%	-0.42%	-0.26%
Net Income (Continuing)	-1.56M	-2.22M	-4.26M	-5.73M	-10.65M	-12.29M	-13.59M	-13.68M	-19.38M	-24.44M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.40	-0.47	-0.72	-0.74	-0.89	-0.78	-0.65	-0.52	-0.60	-0.60
EPS Growth %	0.74%	-0.17%	-0.53%	-0.03%	-0.2%	0.12%	0.17%	0.2%	-0.15%	0%
EPS (Basic)	-0.40	-0.47	-0.72	-0.74	-0.89	-0.78	-0.65	-0.52	-0.60	-0.60
Diluted Shares Outstanding	3.62M	4.74M	5.94M	7.74M	11.99M	15.68M	20.77M	26.44M	32.57M	40.4M
Basic Shares Outstanding	3.62M	4.74M	5.94M	7.74M	11.99M	15.68M	20.77M	26.44M	32.57M	40.4M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	208.11K	1.85M	1.49M	17.97M	8.84M	27.92M	45.44M	33.84M	53.67M	44.61M
Cash & Short-Term Investments	165.69K	1.74M	1.35M	16.82M	7.88M	27.51M	45.11M	33.5M	52.9M	44.15M
Cash Only	165.69K	1.74M	1.35M	16.82M	3.88M	7.41M	4.71M	4.73M	4.54M	3.02M
Short-Term Investments	0	0	0	0	4M	20.1M	40.41M	28.77M	48.35M	41.12M
Accounts Receivable	9.62K	51.97K	80K	646K	823K	0	0	82K	369K	236K
Days Sales Outstanding	-	-	-	471.58	-	-	-	-	-	-
Inventory	1	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	0.1	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	47K	350K	243K	0	0	227K
Total Non-Current Assets+	14.29K	19.39K	308K	367K	217K	174K	112K	560K	485K	1.74M
Property, Plant & Equipment	14.29K	19.39K	37K	96K	217K	174K	112K	560K	485K	427K
Fixed Asset Turnover	-	-	-	5.21x	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	271K	271K	0	0	0	0	0	1.31M
Total Assets+	222.41K	1.87M	1.8M	18.34M	9.05M	28.09M	45.55M	34.4M	54.16M	46.34M
Asset Turnover	-	-	-	0.03x	-	-	-	-	-	-
Asset Growth %	-0.21%	7.42%	-0.04%	9.18%	-0.51%	2.1%	0.62%	-0.24%	0.57%	-0.14%
Total Current Liabilities+	1.06M	626.97K	1M	1.3M	1.32M	2.03M	1.52M	2.17M	2.79M	5.39M
Accounts Payable	674.15K	250K	513K	483K	182K	1.1M	509K	734K	926K	940K
Days Payables Outstanding	55.17K	41.27K	46.81K	-	-	-	-	-	-	-
Short-Term Debt	261.43K	0	0	0	60K	0	0	0	0	0
Deferred Revenue (Current)	33.03K	-200.46K	0	34K	0	0	0	0	0	0
Other Current Liabilities	-264.26K	97.97K	439K	417K	657K	0	0	667K	766K	4.35M
Current Ratio	0.20x	2.96x	1.49x	13.87x	6.70x	13.77x	29.82x	15.61x	19.27x	8.28x
Quick Ratio	0.20x	2.96x	1.49x	13.87x	6.70x	13.77x	29.82x	15.61x	19.27x	8.28x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	388.17K	0	0	18K	118K	53K	3K	400K	317K	237K
Long-Term Debt	389.21K	0	0	18K	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	18K	118K	53K	3K	400K	317K	237K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	-1.03K	0	0	-18K	0	0	0	0	0	0
Total Liabilities	1.45M	626.97K	1M	1.31M	1.44M	2.08M	1.53M	2.57M	3.1M	5.63M
Total Debt+	649.21K	200.46K	0	23K	178K	118K	52K	469K	400K	340K
Net Debt	483.51K	-1.54M	-1.35M	-16.8M	-3.71M	-7.29M	-4.66M	-4.26M	-4.14M	-2.69M
Debt / Equity	-	0.16x	-	0.00x	0.02x	0.00x	0.00x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-29.79x	-51.30x	-	-	-	-	-	-	-	-
Total Equity+	-1.23M	1.25M	799K	17.02M	7.62M	26.01M	44.02M	31.83M	51.06M	40.72M
Equity Growth %	0.2%	2.01%	-0.36%	20.31%	-0.55%	2.42%	0.69%	-0.28%	0.6%	-0.2%
Book Value per Share	-0.34	0.26	0.13	2.20	0.64	1.66	2.12	1.20	1.57	1.01
Total Shareholders' Equity	-1.23M	1.25M	799K	17.02M	7.62M	26.01M	44.02M	31.83M	51.06M	40.72M
Common Stock	28.05M	40.99M	0	0	0	0	0	0	0	0
Retained Earnings	-33.95M	-46.71M	-40.23M	-45.97M	-56.62M	-68.91M	-82.5M	-96.18M	-115.56M	-140M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-20.92K	587.08K	610.88K	-24K	2K	-2K	-51K	-74K	6K	23K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.37M	-3.02M	-3.9M	-5.7M	-9.1M	-9.19M	-12.25M	-11.51M	-18.73M	-22.08M
Operating CF Margin %	-	-	-	-11.39%	-	-	-	-	-	-
Operating CF Growth %	0.64%	-1.21%	-0.29%	-0.46%	-0.6%	-0.01%	-0.33%	0.06%	-0.63%	-0.18%
Net Income	-1.44M	-2.22M	-4.26M	-5.73M	-10.65M	-12.29M	-13.59M	-13.68M	-19.38M	-24.44M
Depreciation & Amortization	4.11K	2.2K	4K	15K	21K	21K	24K	25K	30K	39K
Stock-Based Compensation	125.49K	263.31K	409K	620K	1.16M	1.84M	1.56M	1.5M	1.68M	2.08M
Deferred Taxes	21.54K	-169.95K	84.6K	0	0	0	0	0	0	0
Other Non-Cash Items	-21.54K	22.86K	-93.6K	39K	-25K	48K	219K	53K	-1.15M	-1.27M
Working Capital Changes	-52.97K	-918.45K	-44K	-636K	387K	1.2M	-461K	585K	93K	1.51M
Change in Receivables	-2.78K	-42.36K	-27K	-700K	-43K	483K	210K	48K	-287K	133K
Change in Inventory	0	-32.3K	-756K	-372K	0	0	0	0	0	0
Change in Payables	0	-599.07K	248K	372K	-301K	917K	-590K	225K	192K	14K
Cash from Investing+	-5.39K	-6.89K	-22K	-50K	-3.91M	-16.13M	-20.54M	11.54M	-18.3M	8.56M
Capital Expenditures	-5.39K	-6.89K	-22K	-50K	-2K	-47K	-22K	-81K	-24K	-25K
CapEx % of Revenue	-	-	-	0.1%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	1	0	0	13K	16K	2K	0	0	0
Cash from Financing+	1.37M	4.59M	3.54M	21.22M	70K	28.84M	30.09M	-6K	36.84M	11.99M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-22.56K	470.63K	622K	650K	75K	45K	244K	0	0	256K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.37M	-3.03M	-3.92M	-5.75M	-9.1M	-9.23M	-12.27M	-11.59M	-18.75M	-22.1M
FCF Margin %	-	-	-	-11.49%	-	-	-	-	-	-
FCF Growth %	0.64%	-1.21%	-0.29%	-0.47%	-0.58%	-0.01%	-0.33%	0.06%	-0.62%	-0.18%
FCF per Share	-0.38	-0.64	-0.66	-0.74	-0.76	-0.59	-0.59	-0.44	-0.58	-0.55
FCF Conversion (FCF/Net Income)	0.95x	1.36x	0.92x	0.99x	0.85x	0.75x	0.90x	0.84x	0.97x	0.90x
Interest Paid	0	0	0	11K	2K	2K	0	0	0	0
Taxes Paid	0	0	0	80K	26K	36K	28K	27K	33K	26K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-26983.23%	-416.63%	-64.34%	-86.43%	-73.1%	-38.81%	-36.06%	-46.77%	-53.27%
Return on Invested Capital (ROIC)	-	-	-	-2253.67%	-420.34%	-84.16%	-35.24%	-31.37%	-42.83%	-47.11%
Gross Margin	-	-	-	100%	-	-	-	-	-	-
Net Margin	-	-	-	-1146.8%	-	-	-	-	-	-
Debt / Equity	-	0.16x	-	0.00x	0.02x	0.00x	0.00x	0.01x	0.01x	0.01x
Interest Coverage	-29.79x	-51.30x	-	-	-	-	-	-	-	-
FCF Conversion	0.95x	1.36x	0.92x	0.99x	0.85x	0.75x	0.90x	0.84x	0.97x	0.90x
Revenue Growth	-	-	-	-	-100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

DiaMedica Therapeutics Inc. (DMAC) grew revenue by 0.0% over the past year. Growth has been modest.

DiaMedica Therapeutics Inc. (DMAC) reported a net loss of $31.9M for fiscal year 2024.

Dividend & Returns

DiaMedica Therapeutics Inc. (DMAC) has a return on equity (ROE) of -53.3%. Negative ROE indicates the company is unprofitable.

DiaMedica Therapeutics Inc. (DMAC) had negative free cash flow of $27.8M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

DiaMedica Therapeutics Inc. (DMAC) 10-Year Financial Performance & Capital Metrics

DMAC • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $0
EBITDA -$27M -25.5%
Net Income -$24M -26.1%
EPS (Diluted) -0.60
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -53.27% -13.9%
ROIC -47.11% -10.0%
Debt/Equity 0.01 +6.6%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 90 (top 10%)

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 24.1% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-47.09%

EPS CAGR

10Y-

5Y-

3Y-

TTM-26.79%

ROCE

10Y Avg-233.03%

5Y Avg-51.89%

3Y Avg-48.46%

Latest-57.8%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	500K	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-1%	-	-	-	-	-
Cost of Goods Sold+	4.46K	2.21K	4K	0	0	0	0	0	0	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-4.46K	-2.21K	-4K	500K	0	0	0	0	0	0
Gross Margin %	-	-	-	1%	-	-	-	-	-	-
Gross Profit Growth %	-	0.5%	-0.81%	126%	-1%	-	-	-	-	-
Operating Expenses+	1.31M	2.48M	4.28M	6.05M	11.59M	12.7M	13.65M	14M	21.27M	26.68M
OpEx % of Revenue	-	-	-	12.09%	-	-	-	-	-	-
Selling, General & Admin	423.35K	718.04K	1.31M	2.74M	3.69M	4.49M	4.88M	6.16M	8.16M	7.62M
SG&A % of Revenue	-	-	-	5.48%	-	-	-	-	-	-
Research & Development	886.07K	1.76M	3.21M	4.52M	7.9M	8.21M	8.77M	7.84M	13.11M	19.06M
R&D % of Revenue	-	-	-	9.04%	-	-	-	-	-	-
Other Operating Expenses	3K	0	6K	-68K	0	0	0	0	0	0
Operating Income+	-1.31M	-2.48M	-4.52M	-6.76M	-11.59M	-12.7M	-13.65M	-14M	-21.27M	-26.68M
Operating Margin %	-	-	-	-13.52%	-	-	-	-	-	-
Operating Income Growth %	0.73%	-0.9%	-0.82%	-0.5%	-0.71%	-0.1%	-0.07%	-0.03%	-0.52%	-0.25%
EBITDA+	-1.31M	-2.48M	-4.51M	-6.75M	-11.57M	-12.68M	-13.62M	-13.98M	-21.24M	-26.64M
EBITDA Margin %	-	-	-	-13.49%	-	-	-	-	-	-
EBITDA Growth %	0.73%	-0.9%	-0.82%	-0.49%	-0.72%	-0.1%	-0.07%	-0.03%	-0.52%	-0.25%
D&A (Non-Cash Add-back)	4.11K	2.21K	4K	15K	21K	21K	24K	25K	30K	39K
EBIT	-1.5M	-2.15M	-4.26M	-5.55M	-11.59M	-12.7M	-13.65M	-14M	-21.27M	-26.68M
Net Interest Income+	-42.22K	-46.65K	0	0	0	0	0	0	0	2.3M
Interest Income	1.74K	1.73K	0	0	0	0	0	0	0	2.3M
Interest Expense	43.95K	48.38K	0	0	0	0	0	0	0	0
Other Income/Expense	-104.38K	280.63K	259K	747K	975K	434K	82K	353K	1.93M	2.27M
Pretax Income+	-1.43M	-2.2M	-4.26M	-5.65M	-10.62M	-12.27M	-13.56M	-13.65M	-19.34M	-24.41M
Pretax Margin %	-	-	-	-11.31%	-	-	-	-	-	-
Income Tax+	12.45K	22.31K	-9K	80K	31K	27K	28K	28K	43K	30K
Effective Tax Rate %	1.01%	1.01%	1%	1.01%	1%	1%	1%	1%	1%	1%
Net Income+	-1.44M	-2.22M	-4.26M	-5.73M	-10.65M	-12.29M	-13.59M	-13.68M	-19.38M	-24.44M
Net Margin %	-	-	-	-11.47%	-	-	-	-	-	-
Net Income Growth %	0.7%	-0.54%	-0.92%	-0.35%	-0.86%	-0.15%	-0.11%	-0.01%	-0.42%	-0.26%
Net Income (Continuing)	-1.56M	-2.22M	-4.26M	-5.73M	-10.65M	-12.29M	-13.59M	-13.68M	-19.38M	-24.44M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-0.40	-0.47	-0.72	-0.74	-0.89	-0.78	-0.65	-0.52	-0.60	-0.60
EPS Growth %	0.74%	-0.17%	-0.53%	-0.03%	-0.2%	0.12%	0.17%	0.2%	-0.15%	0%
EPS (Basic)	-0.40	-0.47	-0.72	-0.74	-0.89	-0.78	-0.65	-0.52	-0.60	-0.60
Diluted Shares Outstanding	3.62M	4.74M	5.94M	7.74M	11.99M	15.68M	20.77M	26.44M	32.57M	40.4M
Basic Shares Outstanding	3.62M	4.74M	5.94M	7.74M	11.99M	15.68M	20.77M	26.44M	32.57M	40.4M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	208.11K	1.85M	1.49M	17.97M	8.84M	27.92M	45.44M	33.84M	53.67M	44.61M
Cash & Short-Term Investments	165.69K	1.74M	1.35M	16.82M	7.88M	27.51M	45.11M	33.5M	52.9M	44.15M
Cash Only	165.69K	1.74M	1.35M	16.82M	3.88M	7.41M	4.71M	4.73M	4.54M	3.02M
Short-Term Investments	0	0	0	0	4M	20.1M	40.41M	28.77M	48.35M	41.12M
Accounts Receivable	9.62K	51.97K	80K	646K	823K	0	0	82K	369K	236K
Days Sales Outstanding	-	-	-	471.58	-	-	-	-	-	-
Inventory	1	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	0.1	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	47K	350K	243K	0	0	227K
Total Non-Current Assets+	14.29K	19.39K	308K	367K	217K	174K	112K	560K	485K	1.74M
Property, Plant & Equipment	14.29K	19.39K	37K	96K	217K	174K	112K	560K	485K	427K
Fixed Asset Turnover	-	-	-	5.21x	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	271K	271K	0	0	0	0	0	1.31M
Total Assets+	222.41K	1.87M	1.8M	18.34M	9.05M	28.09M	45.55M	34.4M	54.16M	46.34M
Asset Turnover	-	-	-	0.03x	-	-	-	-	-	-
Asset Growth %	-0.21%	7.42%	-0.04%	9.18%	-0.51%	2.1%	0.62%	-0.24%	0.57%	-0.14%
Total Current Liabilities+	1.06M	626.97K	1M	1.3M	1.32M	2.03M	1.52M	2.17M	2.79M	5.39M
Accounts Payable	674.15K	250K	513K	483K	182K	1.1M	509K	734K	926K	940K
Days Payables Outstanding	55.17K	41.27K	46.81K	-	-	-	-	-	-	-
Short-Term Debt	261.43K	0	0	0	60K	0	0	0	0	0
Deferred Revenue (Current)	33.03K	-200.46K	0	34K	0	0	0	0	0	0
Other Current Liabilities	-264.26K	97.97K	439K	417K	657K	0	0	667K	766K	4.35M
Current Ratio	0.20x	2.96x	1.49x	13.87x	6.70x	13.77x	29.82x	15.61x	19.27x	8.28x
Quick Ratio	0.20x	2.96x	1.49x	13.87x	6.70x	13.77x	29.82x	15.61x	19.27x	8.28x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	388.17K	0	0	18K	118K	53K	3K	400K	317K	237K
Long-Term Debt	389.21K	0	0	18K	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	18K	118K	53K	3K	400K	317K	237K
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	-1.03K	0	0	-18K	0	0	0	0	0	0
Total Liabilities	1.45M	626.97K	1M	1.31M	1.44M	2.08M	1.53M	2.57M	3.1M	5.63M
Total Debt+	649.21K	200.46K	0	23K	178K	118K	52K	469K	400K	340K
Net Debt	483.51K	-1.54M	-1.35M	-16.8M	-3.71M	-7.29M	-4.66M	-4.26M	-4.14M	-2.69M
Debt / Equity	-	0.16x	-	0.00x	0.02x	0.00x	0.00x	0.01x	0.01x	0.01x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-29.79x	-51.30x	-	-	-	-	-	-	-	-
Total Equity+	-1.23M	1.25M	799K	17.02M	7.62M	26.01M	44.02M	31.83M	51.06M	40.72M
Equity Growth %	0.2%	2.01%	-0.36%	20.31%	-0.55%	2.42%	0.69%	-0.28%	0.6%	-0.2%
Book Value per Share	-0.34	0.26	0.13	2.20	0.64	1.66	2.12	1.20	1.57	1.01
Total Shareholders' Equity	-1.23M	1.25M	799K	17.02M	7.62M	26.01M	44.02M	31.83M	51.06M	40.72M
Common Stock	28.05M	40.99M	0	0	0	0	0	0	0	0
Retained Earnings	-33.95M	-46.71M	-40.23M	-45.97M	-56.62M	-68.91M	-82.5M	-96.18M	-115.56M	-140M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-20.92K	587.08K	610.88K	-24K	2K	-2K	-51K	-74K	6K	23K
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-1.37M	-3.02M	-3.9M	-5.7M	-9.1M	-9.19M	-12.25M	-11.51M	-18.73M	-22.08M
Operating CF Margin %	-	-	-	-11.39%	-	-	-	-	-	-
Operating CF Growth %	0.64%	-1.21%	-0.29%	-0.46%	-0.6%	-0.01%	-0.33%	0.06%	-0.63%	-0.18%
Net Income	-1.44M	-2.22M	-4.26M	-5.73M	-10.65M	-12.29M	-13.59M	-13.68M	-19.38M	-24.44M
Depreciation & Amortization	4.11K	2.2K	4K	15K	21K	21K	24K	25K	30K	39K
Stock-Based Compensation	125.49K	263.31K	409K	620K	1.16M	1.84M	1.56M	1.5M	1.68M	2.08M
Deferred Taxes	21.54K	-169.95K	84.6K	0	0	0	0	0	0	0
Other Non-Cash Items	-21.54K	22.86K	-93.6K	39K	-25K	48K	219K	53K	-1.15M	-1.27M
Working Capital Changes	-52.97K	-918.45K	-44K	-636K	387K	1.2M	-461K	585K	93K	1.51M
Change in Receivables	-2.78K	-42.36K	-27K	-700K	-43K	483K	210K	48K	-287K	133K
Change in Inventory	0	-32.3K	-756K	-372K	0	0	0	0	0	0
Change in Payables	0	-599.07K	248K	372K	-301K	917K	-590K	225K	192K	14K
Cash from Investing+	-5.39K	-6.89K	-22K	-50K	-3.91M	-16.13M	-20.54M	11.54M	-18.3M	8.56M
Capital Expenditures	-5.39K	-6.89K	-22K	-50K	-2K	-47K	-22K	-81K	-24K	-25K
CapEx % of Revenue	-	-	-	0.1%	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	1	0	0	13K	16K	2K	0	0	0
Cash from Financing+	1.37M	4.59M	3.54M	21.22M	70K	28.84M	30.09M	-6K	36.84M	11.99M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-22.56K	470.63K	622K	650K	75K	45K	244K	0	0	256K
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-1.37M	-3.03M	-3.92M	-5.75M	-9.1M	-9.23M	-12.27M	-11.59M	-18.75M	-22.1M
FCF Margin %	-	-	-	-11.49%	-	-	-	-	-	-
FCF Growth %	0.64%	-1.21%	-0.29%	-0.47%	-0.58%	-0.01%	-0.33%	0.06%	-0.62%	-0.18%
FCF per Share	-0.38	-0.64	-0.66	-0.74	-0.76	-0.59	-0.59	-0.44	-0.58	-0.55
FCF Conversion (FCF/Net Income)	0.95x	1.36x	0.92x	0.99x	0.85x	0.75x	0.90x	0.84x	0.97x	0.90x
Interest Paid	0	0	0	11K	2K	2K	0	0	0	0
Taxes Paid	0	0	0	80K	26K	36K	28K	27K	33K	26K

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-26983.23%	-416.63%	-64.34%	-86.43%	-73.1%	-38.81%	-36.06%	-46.77%	-53.27%
Return on Invested Capital (ROIC)	-	-	-	-2253.67%	-420.34%	-84.16%	-35.24%	-31.37%	-42.83%	-47.11%
Gross Margin	-	-	-	100%	-	-	-	-	-	-
Net Margin	-	-	-	-1146.8%	-	-	-	-	-	-
Debt / Equity	-	0.16x	-	0.00x	0.02x	0.00x	0.00x	0.01x	0.01x	0.01x
Interest Coverage	-29.79x	-51.30x	-	-	-	-	-	-	-	-
FCF Conversion	0.95x	1.36x	0.92x	0.99x	0.85x	0.75x	0.90x	0.84x	0.97x	0.90x
Revenue Growth	-	-	-	-	-100%	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

DiaMedica Therapeutics Inc. (DMAC) grew revenue by 0.0% over the past year. Growth has been modest.

DiaMedica Therapeutics Inc. (DMAC) reported a net loss of $31.9M for fiscal year 2024.

Dividend & Returns

DiaMedica Therapeutics Inc. (DMAC) has a return on equity (ROE) of -53.3%. Negative ROE indicates the company is unprofitable.

DiaMedica Therapeutics Inc. (DMAC) had negative free cash flow of $27.8M in fiscal year 2024, likely due to heavy capital investments.